ArticlemBio2022
Genomic Diversity across Candida auris Clinical Isolates Shapes Rapid Development of Antifungal Resistance
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Dutch guideline for the prevention and control of multidrug-resistant organisms in the hospital setting, 2024 update.Antimicrobial resistance and infection control · 2025Guideline
- Beyond antifungal susceptibility: molecular mechanisms, detection, and clinical implications of fungal heteroresistance.Molecular biology reports · 2026Review
- Detection of "hidden" mitotic crossovers by long-read DNA sequencing.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Segmental duplications and supernumerary chromosomes drive antifungal drug resistance in Candida auris.Nature communications · 2026Article
- Molecular Epidemiology ofOpen forum infectious diseases · 2026Article
- Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026Article
- Recent Outbreaks, Resistance Trends, and Control Measures inJournal of fungi (Basel, Switzerland) · 2026Review
- Article
- Defining thebioRxiv : the preprint server for biology · 2026Article
- Wastewater intelligence predicts the emergence of clinically-relevant and drug-resistant Candidozyma auris at healthcare facilities.Nature communications · 2026Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- Experimental Evolution of PathogenicMicroorganisms · 2026Review
- Article
- Resistance gene mutations and phylogenetic relationships inFrontiers in cellular and infection microbiology · 2026Article
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
- Genomic characterization of antifungal resistance patterns in Candida auris clade I: A large-scale analysis of 647 global genomes.Northern clinics of Istanbul · 2026Article
- Article
- Article
- Identification and characterization of components of the Candida albicans inner kinetochore.Genetics · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Antifungal drug resistance and tolerance pose a serious threat to global public health. In the human fungal pathogen, Candida auris, resistance to triazole, polyene, and echinocandin antifungals is rising, resulting in multidrug resistant isolates. Here, we use genome analysis and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.